小气道功能障碍与良好控制哮喘患者未来急性加重风险的关系:ATLANTIS观察性研究
严重小气道功能障碍时R5-R20和AX均为独立预测因子。
要点
- 良好控制哮喘患者中小气道功能障碍常见,R5-R20异常者占36%。
- R5-R20定义的小气道功能障碍是未来急性加重的独立危险因素。
- 严重小气道功能障碍时,R5-R20和AX均可独立预测急性加重。
核心结论
- 小气道功能障碍是良好控制哮喘成人未来急性加重的常见、敏感、早期独立风险生物标志物。
研究设计与样本
- ATLANTIS为观察性研究,纳入来自9个国家29家诊所的773例18-65岁哮喘患者,基线为2014年6月30日至2017年3月3日。
主要发现
- 良好控制哮喘患者中,R5-R20定义的小气道功能障碍占36%(95%CI 30-41),AX定义占34%(95%CI 28-42),X5定义占26%(95%CI 21-31)。
临床怎么用
- 对良好控制哮喘患者,可考虑通过脉冲振荡检测小气道功能障碍(尤其R5-R20)以识别未来急性加重高风险个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent surveys suggest that asthma remains inadequately controlled in more than 50% of adults with asthma despite guideline-based standard therapy. Small airways are often under-recognised as major sites of airway obstruction and inflammation. This might be related to lack of assessment with current tools such as impulse oscillometry, and thus under-treatment might explain inadequate control. Small airway dysfunction, which is common in adults with well controlled asthma, might represent an important biomarker of future risk of exacerbations. We aimed to investigate whether small airway dysfunction is present in patients with well controlled asthma and, if so, whether it is a risk factor for future exacerbations in this population. METHODS: The observational Assessment of Small Airways Involvement in Asthma (ATLANTIS) study included 773 extensively characterised patients with asthma aged 18-65 years from 29 primary and specialty clinics in nine countries from June 30, 2014, to March 3, 2017. Patients were required to be diagnosed with asthma at least 6 months before inclusion based on evidence of airway hyper-responsiveness, bronchodilator reversibility, or peak expiratory flow variability. Patients were required to have stable asthma, defined as no asthma exacerbations and regular asthma treatment at a consistent dose for 8 weeks before baseline visits. The current analysis included patients with well controlled asthma, defined as an Asthma Control Questionnaire (ACQ-6) score of less than 0·75 at baseline. Small airway dysfunction was defined, based on deviation from predicted values of impulse oscillometry parameters, as a Z score of more than 1·645 for R5-R20 (resistance at 5 Hz minus resistance at 20 Hz) and AX (area of reactance) and a Z score of less than -1·645 for X5 (reactance at 5 Hz), with additional analyses exploring severe small airway dysfunction (Z score of 3 or -3). ATLANTIS is registered with ClinicalTrials.gov, NCT02123667. FINDINGS: Of 773 patients, ACQ-6 assessments were available for 772 patients. Among these patients, 384 (50%) were classified as having well controlled asthma, and small airway dysfunction was present in 108 (36% [95% CI 30-41]) of 304 patients with impulse oscillometry data available for R5-R20, 89 (34% [28-42]) of 261 patients with data for AX, and 79 (26% [21-31]) of 303 patients with data for X5. In the multivariable analysis, we found that R5-R20-defined small airway dysfunction was associated with increased risk of future exacerbations, independent of age, sex, smoking status, Global Initiative for Asthma steps 4-5, previous exacerbations, percentage of predicted FEV1, ratio of residual volume to total lung capacity, and peripheral blood eosinophil count (hazard ratio [HR] 2·26 [95% CI 1·05-4·85]; p=0·038), whereas AX (2·07 [0·91-4·70]; p=0·082) and X5 (0·86 [0·33-2·21]; p=0·75) were not associated with exacerbations. For severe small airway disease, both R5-R20 (HR 2·80 [95% CI 1·26-6·26]; p=0·012) and AX (2·51 [1·04-6·04]; p=0·041) became independent predictors of future exacerbations, whereas X5 remained non-significant (0·99 [0·29-3·32]; p=0·98). INTERPRETATIONS: We have addressed an undervalued trait by showing that small airway dysfunction is a common, sensitive, early independent risk biomarker for future exacerbations in adults with well controlled asthma. FUNDING: Chiesi Pharmaceuticals and the Dutch Ministry of Health.
引用
- Galant, Kuks, Kole, et al. Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational study. Lancet Respir Med. 2025. PMID: 41038213. doi:10.1016/S2213-2600(25)00283-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。